Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and ...

Equillium Inc (NASDAQ:EQ) stock plunged 12.4% following the company’s announcement that it will integrate cryptocurrency ...

Investing.com -- Equillium Inc (NASDAQ: EQ) stock tumbled 12.4% after the biotechnology company announced plans to integrate cryptocurrency into its treasury reserve strategy, a significant deviation ...

As the U.S. markets react to recent economic uncertainties, including weak job reports and tariff concerns, investors are reassessing their strategies amid fluctuating indices. In this context, penny ...

Equillium, Inc. (NASDAQ:EQ – Get Free Report) traded down 6.1% on Wednesday . The company traded as low as $0.37 and last traded at $0.38. 27,135 shares traded hands during trading, a decline of ...

Shares of NASDAQ:EQ opened at $0.41 on Friday. Equillium has a 1-year low of $0.37 and a 1-year high of $2.43. The stock has a market cap of $14.36 million, a P/E ratio of -2.90 and a beta of 1.87.

Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory ...

Reports Q4 revenue $4.39M vs. $9.21M last year. “This morning, following considerable efforts by our clinical team, we announced topline data from the Phase 3 EQUATOR study evaluating itolizumab ...

The stock option has an exercise price per share equal to $1.07, Equillium’s closing stock price on August 30, and will vest over four years, with 25% of the underlying shares vesting on the one ...

Equillium’s add-on lupus treatment improved a biomarker of kidney function in an unblinded phase 1 study, setting the ball rolling toward Ono Pharmaceuticals’ court for future development work.